| Bioactivity | Lifibrol is a potent and oral activity hypolipidemic agent. Lifibrol decreases the plasma total cholesterol. Lifibrol has the potential for the research of hypercholesterolemia[1][2]. |
| In Vivo | Lifibrol (15, 50 mg/kg; p.o.; daily for 6 days) 可降低血浆总胆固醇含量[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 96609-16-4 |
| Formula | C21H26O4 |
| Molar Mass | 342.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Locker PK, et al. Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group. Clin Pharmacol Ther. 1995 Jan;57(1):73-88. [2]. Bell FP, et al. Action of the new hypolipidemic agent lifibrol (K12.148) on lipid homeostasis in normal rats: plasma lipids, hepatic sterologenesis, and the fate of injected [14C]acetate. Lipids. 1993 Dec;28(12):1079-85. |